EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization

Kira Feldman iD, Kathryn Aaronson, Tina Gu iD, Kelsey Ige iD, Erica Southworth, Lauren Sanchez, Elliot Stieglitz iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Kira Feldman und 6 weiteren Autor:innen. Beteiligte Einrichtung: San Francisco Department of Pediatrics, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Erwinia, Antineoplastic Agents, Drug Hypersensitivity, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alex's Lemonade Stand Foundation, Center of Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pegaspargase is a therapeutic enzyme that is utilized in treatment regimens targeting pediatric acute lymphoblastic leukemia. However, many patients experience hypersensitivity reactions, requiring discontinuation of the therapy. Historically, this necessitated switching to an alternative form of the drug, most commonly asparaginase Erwinia chrysanthemi ; however, in recent years this was difficult due to drug shortages and eventually commercial discontinuation. We report here our experience performing pegaspargase desensitizations in patients with prior hypersensitivity reactions. Procedure Patients with a clinical hypersensitivity reaction to pegaspargase were identified. When due for their next dose, patients were admitted to the pediatric intensive care unit, bone marrow transplant unit, or oncology unit, and underwent desensitization utilizing a rigorous premedication and multistep dilution‐based protocol. Serum asparaginase activity levels were drawn after desensitization to assess for therapeutic levels of enzyme activity.

Results

We identified 11 patients who underwent a total of 33 desensitizations to pegaspargase and calaspargase pegol‐mknl. No patients experienced clinically significant hypersensitivity reactions necessitating stopping the infusion, nor administration of rescue medications. All serum asparaginase activity levels collected demonstrated enzyme activity levels above predefined therapeutic thresholds. Cost analysis revealed substantial savings when patients received asparaginase desensitization over the now commercially available asparaginase E. chrysanthemi (recombinant) rywn.

Conclusions

Performing desensitization to pegaspargase in the pediatric acute lymphoblastic leukemia population is feasible, safe, and effective. It is financially advantageous over available alternative approaches, and requires fewer injections and presentations to care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErwiniaAntineoplastic AgentsDrug HypersensitivityPrecursor Cell Lymphoblastic Leukemia-LymphomaHypersensitivityChildHumansAsparaginasePolyethylene Glycols

Stichwörter der Autor:innen

asparaginasedesensitizationleukemia

Substanzen

pegaspargaseAsparaginaseAntineoplastic AgentsPolyethylene Glycols

Autor:innen und Institutionen

  • San Francisco Department of Pediatrics, University of California, San Francisco, California, USA.
  • Division of Pediatric Oncology, University of California, San Francisco Benioff Children's Hospital, San Francisco, California, USA.
  • Department of Pharmacy, University of California, San Francisco, California, USA.
  • Division of Pediatric Immunology, University of California, San Francisco Benioff Children's Hospital, San Francisco, California, USA.

ORCID-Profile: Kira Feldman, Tina Gu, Kelsey Ige, Elliot Stieglitz

Förderung

  • Alex's Lemonade Stand Foundation, Center of Excellence

Zitieren

APA

Feldman, K., Aaronson, K., Gu, T., Ige, K., Southworth, E., Sanchez, L., & Stieglitz, E. (2024). Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30891

Vancouver

Feldman K, Aaronson K, Gu T, Ige K, Southworth E, Sanchez L, et al. Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30891

BibTeX
@article{Feldman2024,
  author = {Feldman, Kira and Aaronson, Kathryn and Gu, Tina and Ige, Kelsey and Southworth, Erica and Sanchez, Lauren and Stieglitz, Elliot},
  title = {Desensitization using pegaspargase in the era of commercially available Erwinia : A single‐institution report on efficacy, cost, and resource utilization},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30891}
}
Kostenlos starten →